Aquavit Pharmaceuticals has invested in proprietary technologies for more than a decade, building an intellectual-property portfolio at the intersection of personalized medicine, intelligent treatment systems, pharmaceutical preparation, microchannel delivery, skin health, biologics and AI-enabled healthcare.
Invention and registration are the first two disciplines. Enforcement is the third, and it is exercised as a matter of course.
Followed in order, over fifteen years. Each stage left something behind that the next one built on.
The portfolio is built and managed as interconnected platforms rather than isolated filings. Each supports multiple products, indications, delivery systems and partnerships, and the families overlap by design.
Personalized treatment optimization, data intelligence, physician-guided decision support, personalized preparation and longitudinal outcomes.
Systems and methods for controlled intradermal delivery — fixed-depth placement across a broad application area, in aesthetic and therapeutic use.
Drug, biologic, formulation, administration and combination-treatment inventions.
PITO-002 — an independent follow-on patent to the compounding platform, extending it to topical formulations and to the output devices that deliver them.
The evolution of Aquavit's original Big Data architecture into a body of proprietary, purpose-built engines — each addressing a distinct function across development, registration, distribution and clinical practice.
A portfolio designed as a platform, not a collection of isolated patents.
An intelligence platform can inform a treatment. A treatment can incorporate a proprietary composition. A composition can be paired with a precision delivery technology. A delivery technology can generate new treatment approaches. The value is in the connections.
A selection from the granted and published portfolio, with representative applications under prosecution. Unpublished applications, continuation strategy and prosecution detail are not shown.
| Patent or publication | Jurisdiction and status | Technology family | Subject matter |
|---|---|---|---|
| US 9,675,519 | United States Granted 2017 |
Intelligent medicine | System and method for personalized injection treatment — the APOLLO™ platform, carried as program PITO-001 (Personalized Injection Treatment Optimizer). An automated desktop system that prepares a customized injectable combination for an individual patient, records the dose and formulation digitally, and disposes of single-use components automatically. The specification describes application to treatment combinations including vitamins, growth hormone, glucosamine, omega-3, onabotulinumtoxinA and insulin. |
| EP 2667965 | Europe Granted 2016 |
Intelligent medicine | The European grant in the same family — personalized injection treatment, issued ahead of the US patent and establishing European protection for the platform. |
| US 10,106,278 | United States Granted 2018 |
Intelligent medicine · Skin health | A continuation-in-part extending the platform — further compounding embodiments, sensor integration, synchronization with a complementary health-management system, and application to topical treatments as well as injectables. |
| US 2015/0034208 | United States Published |
Intelligent medicine | The published application in the personalized injection treatment family. |
| US 10,980,865 | United States Granted 2021 |
Precision delivery | Direct application system and method for the delivery of bioactive compositions and formulations — microchannel delivery of bioactive compounds into the layers of the skin for aesthetic and therapeutic purposes. |
| US 11,202,753 | United States Granted 2021 |
Pharmaceutical innovation | Systems and methods for generating immune responses using microchannel delivery devices — administration of immunizing agents into the skin via microneedle arrays, supporting self-administration. The programme designated AQV-1122; examined under the USPTO prioritized-examination pilot and allowed in 2021. |
| US 11,878,034 US 10,894,062 |
United States Granted 2024 & 2021 |
Pharmaceutical innovation | Vitamin supplement compositions — two grants covering injectable vitamin compositions developed alongside the delivery platform, and the basis of the IBX-001 formulation family. Further applications in the family are pending. |
| EP 4161627 | Europe Published 2023 |
Precision delivery | Methods for delivering bioactive compositions and formulations to the skin — the microchannel delivery family, published by the World Intellectual Property Organization and by the European Patent Office in April 2023. |
| Application filed 2020 | United States Under prosecution |
Precision delivery | Method for the delivery of exosomes by microchannel technology. |
| Application filed 2020 | United States Under prosecution |
Precision delivery | Method for the treatment of macular degeneration, extending microchannel delivery to ophthalmic routes of administration. |
| Application filed 2020 | United States Under prosecution |
Precision delivery | Method for the detection of allergic reactions using microchannel delivery technology. |
| Application filed 2020 | United States Under prosecution |
Pharmaceutical innovation | Immunotherapeutic compositions against cancer, delivered by microchannel technology. |
Earliest priority in the personalized injection treatment family dates to January 2011. This table is a selection intended to illustrate the shape of the portfolio; it is not a complete schedule of Aquavit's intellectual property, and no representation is made as to scope of claims. Detailed portfolio information is available to counterparties under appropriate confidentiality.
Aquavit holds a substantial estate of registered trademarks — across the United States, Europe, the United Kingdom and further jurisdictions, and across both product and service classes. The marks are not catalogued here.
Trademarks are where intellectual property meets the person paying for the treatment.
A physician choosing a device is relying on a name to tell them what they are buying. That is precisely why the marks attract imitation, and why they are registered in the markets where the products are actually sold rather than only where they were invented.
Registrations are maintained on a continuing basis and the estate is enforced. What the estate is worth is best judged not from a list of registrations but from what happens when one of them is infringed.
Over the course of its development, Aquavit technologies and intellectual-property assets have attracted acquisition interest, strategic investment discussions, licensing transactions and partnership proposals from major participants across pharmaceuticals, medical aesthetics and healthcare technology.
Specific counterparties and terms are confidential.
Aquavit's intellectual-property strategy extends beyond invention. Microchannel technologies have been translated into commercial products in professional use internationally, demonstrating how proprietary technology can move from patent development into global professional use.
The portfolio has been tested against a market, and the test produced a professional brand recognized by physicians internationally — a different order of evidence than a certificate.
It produced a second proof as well: the technology was imitated, which is what happens to intellectual property worth holding.
A patent or a registration is a claim until a court says otherwise. Aquavit has taken that step, and continues to.
In Aquavit Pharmaceuticals, Inc. v. U-Bio Med, Inc., brought against parties manufacturing and distributing counterfeit product, the United States District Court for the Southern District of New York entered judgment in the company's favor, adopting the Report and Recommendation of the Magistrate Judge in full.
The Court found trademark infringement, counterfeiting and defamation; awarded damages together with attorney fees and costs; imposed further sanctions for contemptuous conduct during the proceedings; and granted permanent injunctive relief.
In a parallel matter the company prevailed before the European Union Intellectual Property Office. Enforcement has been pursued in more than one jurisdiction and is conducted on a continuing basis.
Counterfeit injectable product is a patient-safety matter before it is a commercial one, and it is treated accordingly.
Matter of public record. Enforcement is conducted on a continuing basis in the jurisdictions in which the company's rights are held.
Aquavit evaluates opportunities to expand the reach of its technologies through pharmaceutical development, licensing, co-development, strategic partnerships and new applications.
The platforms were built to be extended, and several have applications well beyond the products currently built on them.
Aquavit is interested in conversations with pharmaceutical developers, device manufacturers, research institutions and distribution partners where a technology in this portfolio removes a constraint on something they are already trying to do. Licensing, co-development and strategic partnership are all available structures.